Pipeline and Commercial Insight: Influenza Vaccines - Pandemic threat revitalizes the sector

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-04-06

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges. Demand is highly variable, and only large players are able to cope with the need for annual updates and the costly manufacturing process. However, driven by the increasing pandemic threat, the market is growing fast and is predicted to more than double in size by 2016.


Scope

  • Strategic analysis of the current influenza market across the US, Japan, France, Germany, Italy, Spain and the UK and of key companies in the sector
  • Thorough assessment of underlying commercial and clinical influencers shaping the influenza vaccine market
  • Patient-based forecasts for the influenza vaccine market taking into account recommended vaccination groups and coverage rates in the 7 major markets
  • In-depth comparative analysis of both seasonal and pandemic influenza vaccine pipeline candidates and discussion of their future potential


    • Report Highlights
    The demand for influenza vaccines is highly variable and the time window for the vaccination is limited to just a few months per year. This, in combination with the need for annual updates and the long planning cycles required due to the lengthy egg-based manufacturing process, makes the flu vaccine market a highly challenging sector.

    The pandemic threat has acted as an important driver for the seasonal vaccine market. Rising public awareness of influenza has increased the demand for seasonal vaccination. Government funding provided for pandemic research is also benefiting seasonal vaccine development through technology transfer.

    With Novartis' cell-based Optaflu currently awaiting EU approval and ProteinSciences' baculovirus-based FluBlØk in phase III, new production techniques available are shaping up to change market dynamics. Further advances include adjuvanted vaccines, and, in earlier development stages, DNA- and universal vaccine candidates.


    Reasons to Purchase

  • Review the clinical and commercial factors driving new product decisions in influenza vaccines and the strategies of key players in the market
  • Gain insight through a patient-based forecast and a thorough analysis of the seasonal and pandemic influenza vaccine pipeline
  • Understand where concerns, unmet needs and future opportunities lie by learning about the views of key influenza vaccine opinion leaders

    • Table of Contents

    Other users found this report page using the following search terms: influenza vaccine flu pipeline market vaccine pandemic vaccination problems european threat gsk

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.